The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chemotherapy Effect
- Pancreatic Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Conditions: Advanced pancreatic cancer subjects which were prospectively to receive first-line chemotherapy. Keywords: Advanced pancreatic cancer; paclitaxel liposome; S-1 Interventions: Drug: paclitaxel liposome; Drug:S-1 Phase: Phase IV Study Type: Interventional Study Design: Allocation: Non-rand...
Conditions: Advanced pancreatic cancer subjects which were prospectively to receive first-line chemotherapy. Keywords: Advanced pancreatic cancer; paclitaxel liposome; S-1 Interventions: Drug: paclitaxel liposome; Drug:S-1 Phase: Phase IV Study Type: Interventional Study Design: Allocation: Non-randomized Endpoint Classification: Efficacy/ Safety Study Intervention Model: single arm Primary Purpose: Treatment MedlinePlus related topics: Cancer, Pancreatic Cancer Drug Information available for: paclitaxel liposome?paclitaxel liposome for injection S-1?Tegafur, Gimeracil and Oteracil Potassium Capsules Primary Outcome Measures: To evaluate the Progression Free Survival of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1. Secondary Outcome Measures: To evaluate the Overall Response Rate?overall survival?disease control rate?Quality of Life?adverse events of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1.
Tracking Information
- NCT #
- NCT04581876
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Xian-Jun Yu, MD, PhD Fudan University
Get Well Soon